What's next for gene therapy? Virginia Tech plastics researchers design polymer macromolecules as gene transfer agents
Gene therapy depends upon foreign DNA, even viruses, to deliver genes, therapeutic proteins, or medicine to cells within the body. Many scientists are looking for better chaperones across the cell membrane. Virginia Tech researchers think polymer molecules can be created to do the job.
The research will be presented at the 232nd national meeting of the American Chemical Society in San Francisco Sept. 10 - 14, 2006.
“We are applying our fundamental knowledge in polymer science to gene transfer agents,” said Tim Long, professor of chemistry in the College of Science at Virginia Tech. “We are trying to understand how the structure of the chaperone impacts the efficiency of its ability to transfer DNA across the cell membrane.”
Entire texts have been devoted to the subject, Long said. “But the researchers are usually biologists. Polymer scientists can bring a unique perspective that I think will lead to new advances.”
Long’s graduate student, John M. Layman of Richmond, Va., will share information regarding star-shaped, or highly-branched, molecules, which are extremely effective at transfection. Long’s group has demonstrated that the topology of these particular polymers can be changed. “We can control the molecular shape and number of functional end groups,” said Long. “We think that topology is important because it can influence the strength of the interaction with DNA and permit efficient release of the DNA for protein synthesis.”
Layman will deliver the talk, “Influence of macromolecular architecture on nucleic acid transfection (POLY 611),” at 4 p.m., Wednesday, Sept. 13, in the Marriott Salon 14/15 as part of the International Biorelated Polymers Symposium. Authors are Layman, Anjali A. Hirani of the Virginia Tech-Wake Forest School of Biomedical Engineering (VT-WF SBES), Joseph M. Pickel and Phillip F. Britt of the Oak Ridge National Laboratory Chemical Sciences Division, Yong Woo Lee at VT-WF SBES, and Long.
“The paper defines a new paradigm for research,” said Long. Layman, whose bachelor of science degree is from Virginia Commonwealth University in chemical engineering, “typifies the way we are going to educate students in the future,” Long said. “He is an engineer working in chemistry on gene therapy. He collaborates with researchers in the Virginia Tech-Wake Forest School of Biomedical Engineering and Oak Ridge National Laboratory.
Layman is funded by the Macromolecular Interfaces with Life Sciences (MILES) National Science Foundation Integrative Graduate Education and Research Traineeship (IGERT) program at Virginia Tech. This fall he will go to study with Brigitte Voit at the Max Bergman Institute in Dresden. (www.ipfdd.de/people/voit/homepage.html)
Learn about Layman's research at http://www.chem.vt.edu/chem-dept/tlong/ under the “Non-viral nucleic acid transfer agents” link.